FDA Clearance Accelerates D3 Bio’s Oncology Programs The U.S. Food and Drug Administration (FDA) has granted clearance for two Investigational New Drug (IND) applications from D3 Bio, a global clinical‑stage biotechnology company focused on transforming cancer therapy. The approvals authorize a Phase 1 trial of D3S‑003 and a Phase 2 study examining Elisrasib (D3S‑001) in…